Promising clinical data from dose escalation in a phase ib/ii ongoing study of mosunetuzumab with polatuzumab vedotin for relapsed/refractory b‐cell non‐hodgkin’s lymphoma
Hematological Oncology(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要